|
|
 | | | |
- close
- close
- close
- close
StreetInsider.com
May 13
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/RBC+Capital+Upgrades+Pharmacyclics+%28PCYC%29+to+Outperform/8329548.html for the full story.
Forbes
Apr 23
Comment
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Pharmacyclics, Inc. (NASD: PCYC) was identified as having a larger market cap than the smaller end of the S&P 500, for example Interpublic Group of...
Stock Blog Hub
Apr 21
Comment
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus chlorambucil in elderly patients suffering from chronic...
Benzinga
Apr 11
Comment
Pharmacyclics (NASDAQ: PCYC) announced today that the Phase III clinical trial (RESONATE™-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic...
Benzinga
Apr 8
Comment
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational
oral agent ibrutinib which demonstrated rapid and sustained disease control as
a monotherapy in untreated, relapsed and refractory chronic...
FierceBiotech
Apr 8
Comment
Already sky-high expectations for the experimental cancer drug ibrutinib from J&J ($JNJ) and Pharmacyclics ($PCYC) managed to arc even higher this morning after the collaborators spread word that the program had just won its third "breakthrough...
Benzinga
Apr 8
Comment
Pharmacyclics (NASDAQ: PCYC) announced today that the U.S. Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic...
Forbes
Apr 6
Comment
Today, Pharmacyclics is a $5.3B company, a value attributable largely to its promising lead compound, ibrutinib, currently in late clinical development for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, and under investigation for a...
Benzinga
Mar 20
Comment
Wedbush maintained Pharmacyclics (NASDAQ: PCYC) with an Outperform rating and increased the price target from $110.00 to $165.00.
Wedbush analyst Gregory Wade commented, "We expect breakthrough designation in MCL to lead to earlier approval of...
StreetInsider.com
Mar 8
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Pharmacyclics+%28PCYC%29+Prices+2.2M+Stock+Offering/8169012.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
